Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease

[1]  I. Hisatome,et al.  Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomised controlled trial. , 2021, Rheumatology.

[2]  I. Shimomura,et al.  Increased plasma XOR activity induced by NAFLD/NASH and its possible involvement in vascular neointimal proliferation , 2021, JCI insight.

[3]  M. Ohishi,et al.  J-shaped curve for the association between serum uric acid levels and the prevalence of blood pressure abnormalities , 2021, Hypertension Research.

[4]  K. Shimamoto,et al.  Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication , 2021, Hypertension Research.

[5]  H. Itoh,et al.  Association of childhood anthropometric measurements and laboratory parameters with high blood pressure in young adults , 2021, Hypertension Research.

[6]  K. Kario,et al.  Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia , 2021, Journal of clinical hypertension.

[7]  I. Shimomura,et al.  Plasma xanthine oxidoreductase activity in Japanese patients with type 2 diabetes across hospitalized treatment , 2020, Journal of diabetes investigation.

[8]  T. Cameron Waller,et al.  Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial , 2020, The Lancet.

[9]  R. Terkeltaub,et al.  Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  M. Kolber,et al.  Treat‐to‐Target in Gout Management? Comment on the Article by FitzGerald et al , 2020, Arthritis & rheumatology.

[11]  Marenao Tanaka,et al.  U-shaped relationship between serum uric acid level and decline in renal function during a 10-year period in female subjects: BOREAS-CKD2 , 2020, Hypertension Research.

[12]  David W. Johnson,et al.  Effects of Allopurinol on the Progression of Chronic Kidney Disease. , 2020, The New England journal of medicine.

[13]  J. McGill,et al.  Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. , 2020, The New England journal of medicine.

[14]  D. Feig.  Urate-Lowering Therapy and Chronic Kidney Disease Progression. , 2020, The New England journal of medicine.

[15]  M. Lanaspa,et al.  Uric acid and hypertension , 2020, Hypertension Research.

[16]  T. Arimoto,et al.  Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction , 2020, ESC heart failure.

[17]  G. Guyatt,et al.  2020 American College of Rheumatology Guideline for the Management of Gout , 2020, Arthritis & rheumatology.

[18]  M. Lanaspa,et al.  Fructose Production and Metabolism in the Kidney. , 2020, Journal of the American Society of Nephrology : JASN.

[19]  K. Kario,et al.  Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial , 2020, PLoS medicine.

[20]  Y. Moriwaki,et al.  Japanese Society of Gout and Uric & Nucleic Acids 2019 Guidelines for Management of Hyperuricemia and Gout 3rd edition , 2020 .

[21]  M. Lanaspa,et al.  The Optimal Range of Serum Uric Acid for Cardiometabolic Diseases: A 5-Year Japanese Cohort Study † , 2020, Journal of clinical medicine.

[22]  Yawen Chen,et al.  Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta‐analysis of randomised controlled trials , 2020, Internal medicine journal.

[23]  H. Kono,et al.  Soluble Uric Acid Promotes Atherosclerosis via AMPK (AMP-Activated Protein Kinase)-Mediated Inflammation , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[24]  K. Yamagishi,et al.  Serum uric acid and risk of stroke and its types: the Circulatory Risk in Communities Study (CIRCS) , 2020, Hypertension Research.

[25]  M. Kanbay,et al.  The causality between the serum uric acid level and stroke , 2020, Hypertension Research.

[26]  T. Ninomiya,et al.  Serum uric acid levels and cardiovascular mortality in a general Japanese population: the Hisayama Study , 2020, Hypertension Research.

[27]  B. Cheung,et al.  Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. , 2019, Rheumatology.

[28]  Y. Ohno,et al.  Hyperuricemia predicts the risk for developing hypertension independent of alcohol drinking status in men and women: the Saku study , 2019, Hypertension Research.

[29]  R. Diaz,et al.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.

[30]  M. Suematsu,et al.  Xanthine oxidase inhibitor ameliorates postischemic renal injury in mice by promoting resynthesis of adenine nucleotides. , 2019, JCI insight.

[31]  H. Koyama,et al.  Xanthine oxidoreductase activity correlates with vascular endothelial dysfunction in patients with type 1 diabetes , 2019, Acta Diabetologica.

[32]  I. Hisatome,et al.  Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy , 2019, European heart journal.

[33]  S. Ito,et al.  Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  Y. Kihara,et al.  Hyperuricemia and endothelial function: From molecular background to clinical perspectives. , 2018, Atherosclerosis.

[35]  K. Shimamoto,et al.  Plasma Xanthine Oxidoreductase Activity as a Novel Biomarker of Metabolic Disorders in a General Population. , 2018, Circulation journal : official journal of the Japanese Circulation Society.

[36]  E. Fukusaki,et al.  Hypoxanthine Secretion from Human Adipose Tissue and its Increase in Hypoxia , 2018, Obesity.

[37]  Kenneth G Saag,et al.  Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout , 2018, The New England journal of medicine.

[38]  S. Zhuang,et al.  Recent advances on uric acid transporters , 2017, Oncotarget.

[39]  H. Campbell,et al.  Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies , 2017, British Medical Journal.

[40]  Y. Moriwaki,et al.  Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans. , 2017, Metabolism: clinical and experimental.

[41]  M. Oka,et al.  A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[42]  M. Nagai,et al.  Serum Uric Acid and Mortality Form Cardiovascular Disease: EPOCH-JAPAN Study. , 2016, Journal of atherosclerosis and thrombosis.

[43]  E. Kelley.  A new paradigm for XOR-catalyzed reactive species generation in the endothelium , 2015, Pharmacological reports : PR.

[44]  F. Martinon,et al.  Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation , 2015, Nature Communications.

[45]  A. Hirayama,et al.  A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  L. Polito,et al.  Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. , 2014, Biochimica et biophysica acta.

[47]  Ping Zhu,et al.  Serum Uric Acid Is Associated with Incident Chronic Kidney Disease in Middle-Aged Populations: A Meta-Analysis of 15 Cohort Studies , 2014, PloS one.

[48]  A. So,et al.  Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice , 2014, Scientific Reports.

[49]  Lan Huang,et al.  Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. , 2013, Atherosclerosis.

[50]  D. Feig,et al.  Uric Acid Reduction Rectifies Prehypertension in Obese Adolescents , 2012, Hypertension.

[51]  T. Asano,et al.  Xanthine Oxidoreductase Is Involved in Macrophage Foam Cell Formation and Atherosclerosis Development , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[52]  Richard J. Johnson,et al.  Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. , 2008, JAMA.

[53]  K. Kodama,et al.  Serum uric acid concentration as a risk factor for cardiovascular mortality: a longterm cohort study of atomic bomb survivors. , 2005, The Journal of rheumatology.

[54]  S. Marklund,et al.  Binding of Xanthine Oxidase to Vascular Endothelium , 1999, The Journal of Biological Chemistry.

[55]  S. Yamashita,et al.  Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. , 1998, Metabolism: clinical and experimental.

[56]  F. Stirpe,et al.  Effects of hypoxia and ethanol on xanthine oxidase of isolated rat hepatocytes: conversion from D to O form and leakage from cells. , 1992, Chemico-biological interactions.

[57]  J. Gollan,et al.  Enhanced activity of the free radical producing enzyme xanthine oxidase in hypoxic rat liver. Regulation and pathophysiologic significance. , 1991, The Journal of clinical investigation.

[58]  L. Sánchez-Lozada.  The Pathophysiology of Uric Acid on Renal Diseases. , 2018, Contributions to nephrology.

[59]  S. Yamashita,et al.  Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. , 1986, International journal of obesity.